068760 — Celltrion Pharm Balance Sheet
0.000.00%
- KR₩2tn
- KR₩2tn
- KR₩478bn
Annual balance sheet for Celltrion Pharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 29,748 | 88,161 | 44,093 | 32,211 | 63,480 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 142,016 | 174,008 | 187,608 | 222,499 | 218,500 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 230,954 | 331,140 | 311,918 | 364,831 | 391,673 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 248,256 | 241,925 | 228,243 | 220,762 | 222,697 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 548,075 | 637,884 | 599,725 | 641,644 | 669,462 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 184,927 | 259,914 | 211,998 | 249,346 | 247,650 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 247,514 | 305,916 | 242,938 | 264,978 | 272,541 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 300,561 | 331,969 | 356,787 | 376,666 | 396,922 |
Total Liabilities & Shareholders' Equity | 548,075 | 637,884 | 599,725 | 641,644 | 669,462 |
Total Common Shares Outstanding |